Please assess the completion status of the following clinical trial:

Trial Title: Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is informed of the investigational nature of this study and has given written, witnessed informed consent in accordance with institutional, local and national guidelines;~* Males or females ≥ 18 and ≤ 85 years of age. Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice an adequate form of contraception for at least 4 weeks prior to study start, and must be willing to continue contraception for at least 4 weeks after the last dose of study drug;~* Chronic kidney disease stage 3 or 4 (estimated Glomerular filtration rate \[GFR\] of 15-60 mL/min within 28 days prior to study drug administration) and not expected to begin dialysis for at least 12 weeks;~* Two hemoglobin values of ≥ 9.0 and \< 11.0 g/dL within 14 days prior to study drug administration, including at least one of the values drawn within 7 days prior to study drug administration;~* One serum ferritin level ≥ 100 micrograms per liter (μg/L) and transferrin saturation ≥ 20 % within 4 weeks prior to study drug administration;~* One serum or red cell folate level above lower limit of normal within 4 weeks prior to study drug administration;~* One vitamin B12 level above lower limit of normal within 4 weeks prior to study drug administration;~* Weight ≥ 45 kg within 4 weeks prior to study drug administration;~* One white blood cell count ≥ 3.0 x 10\^9/L within 4 weeks prior to study drug administration; and~* One platelet count ≥ 100 x 10\^9/L within 4 weeks prior to study drug administration.~Exclusion Criteria:~* Prior treatment with any erythropoiesis stimulating agent in the 12 weeks prior to study drug administration;~* Any prior treatment with Eprex®;~* Known intolerance to any erythropoiesis stimulating agent;~* History of antibodies to any erythropoiesis stimulating agent or history of pure red cell aplasia;~* Prior hemodialysis or peritoneal dialysis treatment;~* Known intolerance to parenteral iron supplementation;~* Red blood cell transfusion within 12 weeks prior to study drug administration;~* Hemoglobinopathy \[e.g., homozygous sickle-cell disease (sickle-cell trait does not exclude patient), thalassemia of all types, etc.\];~* Known hemolysis;~* Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.);~* C Reactive Protein (CRP) greater than 30 mg/L within the 4 weeks prior to study drug administration;~* Febrile illness within 7 days prior to study drug administration;~* Uncontrolled or symptomatic secondary hyperparathyroidism;~* Poorly controlled hypertension within 4 weeks prior to study drug administration, per Investigator's clinical judgment (e.g. systolic ≥ 170mm Hg, diastolic ≥ 100 mm Hg on repeat readings);~* Epileptic seizure in the 6 months prior to study drug administration;~* Chronic congestive heart failure (New York Heart Association Class IV);~* High likelihood of early withdrawal or interruption of the study;~* Evidence of malignancy within the past 5 years (except non-melanoma skin cancer which is not an exclusion criterion);~* Life expectancy \< 12 months;~* Anticipated elective surgery during the study period; and~* Previous exposure to any investigational agent within 6 weeks prior to administration of study drug or planned receipt during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
- Cohort 2 (Type: EXPERIMENTAL): Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
- Cohort 3 (Type: EXPERIMENTAL): Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
- Cohort 4 (Type: EXPERIMENTAL): Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
- Cohort 5 (Type: EXPERIMENTAL): Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
- Cohort 6 (Type: EXPERIMENTAL): Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
- Cohort 7 (Type: EXPERIMENTAL): Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
- Cohort 8 (Type: EXPERIMENTAL): Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete